Open Access

REVIEW

Botulinum toxin A in idiopathic overactive bladder: a narrative review of 5410 cases

Salim Lachkar^*, Ahmed Ibrahimi, Imad Boualaoui, Hachem El Sayegh, Yassine Nouini

Department of Urology A, Ibn Sina University Hospital, Bettouga Avenue, Rabat, 10000, Morocco

* Corresponding Author: Salim Lachkar. Email:

Canadian Journal of Urology 2025, 32(3), 145-165. https://doi.org/10.32604/cju.2025.064912

Received 27 February 2025; Accepted 23 April 2025; Issue published 27 June 2025

Abstract

Introduction: When conservative treatments fail, botulinum toxin A (BoNT-A) is an option for refractory idiopathic overactive bladder (OAB). This review evaluates the efficacy, safety, and predictive factors for BoNT-A in this situation. Material and Methods: A literature search up to January 2025 was performed using PubMed, Google Scholar, and Embase to assess efficacy, safety, and predictors of adverse events (AE) related to BoNT-A. The risk of bias was assessed using the Risk of Bias 2 (RoB 2) tool for randomized studies and the Critical Appraisal Skills Programme (CASP) checklist for cohort studies. The quality of the review was evaluated based on the Oxford criteria, following the Strengthening the Assessment of Narrative Review Articles (SANRA) guidelines, and by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for systematic reviews. Results: 31 studies were included, involving 5410 patients. BoNT-A improves OAB symptoms even after reinjections. Higher doses do not enhance efficacy but increase AE. AE includes high post-void residual (PVR), clean intermittent self-catheterization (CISC), and Urinary Tract Infection (UTI). Predictors of CISC include age, male gender, hysterectomy, ≥3 vaginal deliveries, mixed incontinence, prior mid-urethral sling (MUS), high PVR, low Pressure at Pdet at First Micturition (PIP1) in women, low Bladder Compliance Index (BCI) in men, and high Bladder Outlet Obstruction Index (BOOI). Diabetes and heart failure increase PVR. UTIs are more frequent in women and men with benign prostatic hyperplasia, with CISC increasing the risk fivefold. Severe complications are rare. Predictors of poor response include male gender, high BOOI, low urinary flow, and diabetes. Discussion: BoNT-A is effective for OAB, especially for incontinence. AE is dose-dependent and limits treatment adherence. Their link with poor response remains unclear. Conclusion: BoNT-A effectively treats refractory idiopathic OAB, improving symptoms and quality of life with repeated injections.

---

Keywords

---